WikiProject iconPharmacology Project‑class
WikiProject iconThis page is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
ProjectThis page does not require a rating on Wikipedia's content assessment scale.
WikiProject Pharmacology General information Project page talk Manual of Style talk Reliable sources talk Popular pages talk Departments  → Assessment (Log) talk  → Research talk  → Editor outreach talk How to help Requested articles (1) / (2) Cleanup list Other content Categorization Structure diagrams Photographs Templates Workspace Historical Resources for editors talk Participants talk .mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:": "}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:" · ";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:" (";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:")";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:" "counter(listitem)"\a0 "}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:" ("counter(listitem)"\a0 "}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}@media screen{ .mw-parser-output .navbar li a abbr{color:var(--color-base)!important))@media screen and (prefers-color-scheme:dark){ .mw-parser-output .navbar li a abbr{color:var(--color-base)!important))vte


Howdy folks, I’ve been invited by

WhatamIdoing to contribute here and at the Medicine project. I’m a subject matter expert in these fields with >15 yrs experience across various fields of medicine, including product development, patient care, and basic science. I welcome you to reach out for support with existing articles or to contribute to new topics. See you around! Gobucks821 (talk) 14:57, 17 January 2024 (UTC)[reply]

@Gobucks821: A (rather belated!) welcome over here. There don't seem to be many of us watching WikiProject Pharmacology! Regardless, let's push on. It will be great to have you working on this project too! Klbrain (talk) 09:10, 7 May 2024 (UTC)[reply]


The article leonurine was tagged with the ((More medical citations needed)) warning template in 2021. Since then, the article has accumulated much more content that appears to be supported only low-quality references and/or primary references that are inconsistent with Wikipedia:Identifying reliable sources (medicine). If someone with subject expertise could have a look, particularly at the "Pharmacology" section, that would be appreciated. Thank you. Marbletan (talk) 20:48, 6 February 2024 (UTC)[reply]


I noticed a gap in the coverage of this specific triglyceride with a lot of work being done in recent decades, tricaprin, and would like some eyes on it as I work on getting the article ready for mainspace. I'm new to working on chemical articles with pharmacological applications and want to make sure I'm not putting in primary research to support medical claims here or otherwise giving undue weight to certain applications: Draft:Tricaprin Reconrabbit 17:04, 12 April 2024 (UTC)[reply]

I've had a look at your draft; you are using primary sources, but you're using them as a statement of fact (that there are clinical trials for ...) rather than a claim of utility (that they are helpful for ...). So, my view is that what you've written is fine and helpful! Klbrain (talk) 09:07, 7 May 2024 (UTC)[reply]
I only felt comfortable using language stronger than just "has been studied" when citing the NCI Dictionary. Thanks for taking a look. Once the production info is filled in I will publish. Reconrabbit 12:15, 7 May 2024 (UTC)[reply]

Sunobinop improvements[edit]

Greetings! I'm Valentine, an employee of Imbrium Therapeutics, the company developing sunobinop. Because of my conflict of interest, I posted suggestions to improve the sunobinop article at Talk:Sunobinop#Sunobinop article improvements and included the template for requesting an edit. I'm posting here since it's a more specialized topic and I thought this group might be interested. Thanks, ImbriumValentine (talk) 20:10, 6 May 2024 (UTC)[reply]

 Done Klbrain (talk) 09:00, 7 May 2024 (UTC)[reply]

Integrate definitive new findings[edit]

Much of the staggering mortality rates and health care costs associated with drug-induced liver injury (DILI) is clearly linked to 11 drugs not well-known for their hepatotoxic risk, per the editorial accompanying, which just came out.[1] Lets get this added to the 11 to 17 relevant articles, liver failure, etc.RememberOrwell (talk)


  1. ^ Torgersen, Jessie; Mezochow, Alyssa K.; Newcomb, Craig W.; Carbonari, Dena M.; Hennessy, Sean; Rentsch, Christopher T.; Park, Lesley S.; Tate, Janet P.; Bräu, Norbert; Bhattacharya, Debika; Lim, Joseph K.; Mezzacappa, Catherine; Njei, Basile; Roy, Jason A.; Taddei, Tamar H.; Justice, Amy C.; Lo Re, Vincent (24 June 2024). "Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data". JAMA Internal Medicine. doi:10.1001/jamainternmed.2024.1836. ISSN 2168-6106.
This is a cohort study, which is classified as primary. Per WP:MEDRS, secondary sources (review articles) are needed to support medical claims. Furthermore the accompanying editorial describes this cohort study as an "innovative methodologic approach". We need to wait for this study to be evaluated in reliable secondary sources before citing those secondary sources. Boghog (talk) 05:46, 26 June 2024 (UTC)[reply]
Thanks for the feedback and help. I see that per the verifiability policy, "If available, academic and peer-reviewed publications are usually the most reliable sources on topics such as history, medicine, and science." Given the size of the study, risk of bias, and the source (JAMA), it seems solid enough, but if reliable sources differ, that matters. I don't want to jump the gun, but I'm not convinced we need to wait. Also, the editorial IS a secondary source. LOL, you've made ~leetk (1337k) edits, Boghog. RememberOrwell (talk) 07:17, 26 June 2024 (UTC)[reply]
Seven (stavudine (86.4 eptkpy), erlotinib, lenalidomide ?"or"? thalidomide, chlorpromazine, metronidazole, prochlorperazine, isoniazid) had 10+ events per 10 000 person-years (eptkpy), while ten (moxifloxacin, azathioprine, levofloxacin, clarithromycin, ketoconazole, fluconazole, captopril, amoxicillin-clavulanate, sulfamethoxazole-trimethoprim, ciprofloxacin) had 5-10 eptkpy. Eleven of these (64%) were not included in the highest hepatotoxicity category of LiverTox. RememberOrwell (talk) 05:23, 29 June 2024 (UTC)[reply]